

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Leukemia	c-Myc (MYC)	<i>In vitro</i> studies suggest genomic c-Myc quadruplex DNA could be used to treat leukemia. In human leukemic cell lines, an oligonucleotide encoding the quadruplex-forming c-Myc promoter sequence decreased c-Myc mRNA, protein expression and cellular proliferation and increased cell death compared with a mutated c-Myc promoter sequence that could not form a quadruplex structure. Ongoing work includes IND-enabling toxicity and efficacy studies.	Patented; licensed to Advanced Cancer Therapeutics LLC	Sedoris, K.C. <i>et al. Mol. Cancer Ther.</i> ; published online Nov. 14, 2011; doi:10.1158/1535-7163.MCT-11-0515 <b>Contact:</b> Donald M. Miller, University of Louisville, Louisville, Ky. e-mail: <a href="mailto:donaldmi@ulh.org">donaldmi@ulh.org</a>
		<b>SciBX 4(48); doi:10.1038/scibx.2011.1351</b> Published online Dec. 15, 2011		